Last deal

$50M

Amount

Series B

Stage

09.12.2021

Date

1

all rounds

$50M

Total amount

date founded

Financing round

General

About Company
OncoMyx Therapeutics is a company that develops oncolytic immunotherapies using a unique virus called myxoma to treat cancer.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2018

Number of employees

Last funding type

Series B

IPO status

Private

Description

Founded in 2018 and based in Phoenix, Arizona, OncoMyx Therapeutics utilizes the myxoma virus (MYXV) platform to target hematologic and solid tumors. The company's patented systemic delivery approach allows the myxoma virus to be carried by human leukocytes, enabling it to infect tumor cells. With two decades of research behind it, OncoMyx Therapeutics is developing a 3-in-1 cancer-killing immunotherapy based on the unique properties of myxoma.
Contacts

Social url

Similar Companies
1000
Viron Inc.

Viron Inc.

OncoMyx Therapeutics is developing an oncolytic virus that can be carried systemically by human leukocytes.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Boston, MA, USA

total rounds

2

total raised

$75M
Abalos Therapeutics

Abalos Therapeutics

Abalos Therapeutics is a company developing a novel immuno-virotherapy to fight cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Essen, Germany

total rounds

2

total raised

$49.17M
Cambium Oncology

Cambium Oncology

Cambium Oncology develops immuno-oncology therapeutics targeting a novel checkpoint pathway.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Atlanta, GA, USA
ImmVirX

ImmVirX

ImmVirX develops oncolytic viruses for cancer immunotherapy.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

New Lambton NSW 2305, Australia

total rounds

3

total raised

$50M

Financials

Funding Rounds
1
1

Number of Funding Rounds

$50M

Money Raised

Their latest funding was raised on 09.12.2021. Their latest investor Korea Investment Partners. Their latest round Series B

Date 
Funding Round 
Investors 
Money Raised 
Lead 
B Capital Group

B Capital Group

B Capital Group is a venture capital firm that invests in global entrepreneurs in the field of information technology.

Sector

General Industrials

Subsector

Diversified Industrials

Location

Manhattan Beach, CA 90266, USA

count Of Investments

199

count Of Exists

5
Lumira Ventures

Lumira Ventures

Lumira Ventures is a leading North American healthcare and life sciences venture capital firm.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Toronto, ON, Canada

count Of Investments

89

count Of Exists

10
Co-Investors
Investors
9
2

Number of lead investors

9

Number of investors

Investor 
Lead 
Round 
Partners 
Korea Investment Partners

Korea Investment Partners

Korea Investment Partners: Leading venture capital & private equity firm with 30+ years experience.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Seoul, South Korea

count Of Investments

383

count Of Exists

16
Boehringer Ingelheim Venture Fund

Boehringer Ingelheim Venture Fund

Boehringer Ingelheim Venture Fund invests in therapeutic biotechnology companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Venture Capital, Biotechnology, Financial Services

Location

Ingelheim am Rhein, Germany

count Of Investments

71

count Of Exists

7
Delos Capital

Delos Capital

Delos Capital is a private equity investment firm based in New York City.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

New York, NY, USA

count Of Investments

27

Activity

Recent News
0